Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis – a comparison of esomeprazole with other PPIs

  title={Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis – a comparison of esomeprazole with other PPIs},
  author={S. Edwards and T. Lind and L. Lundell},
  journal={Alimentary Pharmacology \& Therapeutics},
No randomized controlled trial has compared all the licensed standard dose proton pump inhibitors in the healing of reflux oesophagitis. 
Systematic review: standard‐ and double‐dose proton pump inhibitors for the healing of severe erosive oesophagitis – a mixed treatment comparison of randomized controlled trials
This data indicates that the use of a second PPIs in combination with chemotherapy for the healing of severe erosive oesophagitis is a viable treatment option. Expand
The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor
Background:  Some patients with gastro‐oesophageal reflux disease (GORD) remain symptomatic despite proton pump inhibitor (PPI) treatment. There is a need to determine the most appropriate managementExpand
Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression
Little is known regarding patient characteristics that influence the speed of reflux oesophagitis (RO) healing.
Meta‐analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection
This meta‐analysis sought to assess the clinical and safety profiles of esomeprazole versus omeprazole at pharmacologically equivalent doses in healing gastroesophageal reflux disease, peptic ulcer disease and eradicating Helicobacter pylori infection. Expand
The impact of intensifying acid suppression on sleep disturbance related to gastro‐oesophageal reflux disease in primary care
Sleep disturbance is common in patients with GERD but there has been little evaluation of this problem in primary care in patients already taking therapy.
Potential Options to Optimize Therapy of Gastroesophageal Reflux Disease with Proton Pump Inhibitors
The use of PPIs with the strongest antisecretory properties might reveal to be more adequate and cost-effective, particularly for this indication, as this condition appears to be less responsive to PPIs. Expand
Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
In elderly patients, pantoprazole and rabeprazoles were significantly more effective than omeprazole in healing esophagitis and than omEPrazole or lansoprazoles in improving symptoms. Expand
Rabeprazole for the treatment of acid-related disorders
Proton pump inhibitors are widely used for the treatment of acid-related disorders. Rabeprazole is a potent and irreversible inhibitor of H+/K+-ATPase gastric pump, and it is indicated for theExpand
Emerging drugs for gastroesophageal reflux disease
Recent data, however, suggest that the therapeutic efficacy of acid suppression may have reached its maximum and other mechanisms may have to be targeted to further improve symptom control. Expand
Courses for horses: Rethinking the use of proton pump inhibitors in the treatment of equine gastric ulcer syndrome
The purpose of this article is to review the factors that affect oral omeprazole efficacy, with the goal of maximising therapeutic response, and the novel PPIs recently described. Expand


Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis
Esomeprazole is a new proton pump inhibitor, which has been compared to omeprazole for the treatment of reflux oesophagitis in clinical trials.
Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro‐oesophageal reflux disease and peptic ulcer disease
Background : Five proton pump inhibitors are now available for use in North America. Claims of differences in the clinical efficacy of different strengths and/or agents have been made.
Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial
The pharmacologic profile of the new proton pump inhibitor esomeprazole has demonstrated advantages over omeprazole that suggest clinical benefits for patients with acid‐related disease.
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study
Aim:  To assess the efficacy of the 8‐week therapy with esomeprazole 40 mg vs. pantoprazole 40 mg for healing erosive oesophagitis (EE) as part of a management study.
Meta‐analysis: comparing the efficacy of proton pump inhibitors in short‐term use
This work has shown that controlling expenses on proton pump inhibitors would yield great economic benefits for Dutch health care. Expand
Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis
This data indicates that esomeprazole was more effective than lansoprazole and omeprazole in healing moderate or severe erosive oesophagitis (EE). Expand
40 mg Pantoprazole and 40 mg Esomeprazole Are Equivalent in the Healing of Esophageal Lesions and Relief from Gastroesophageal Reflux Disease–related Symptoms
In patients with gastroesophageal reflux disease, 40 mg pantoprazole daily and 40 mg esomeprazoles daily are equally effective for healing of esophageAL lesions and relieving gastroesphagealReflux disease–related symptoms. Expand
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial
Esomeprazoles demonstrates significantly greater efficacy than omeprazole in the treatment of GERD patients with erosive esophagitis and the tolerability and safety of esomeprazole are comparable to that of omepazole. Expand
Evidence for Therapeutic Equivalence of Lansoprazole 30mg and Esomeprazole 40mg in the Treatment of Erosive Oesophagitis
In erosive oesophagitis, lansoprazole 30mg once daily and esomeprazole 40mgonce daily are equally effective in healing erosions and relieving heartburn. Expand
Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis
Esomeprazoles (40 mg) is more effective than lansoprazole (30 mg) in healing erosive esophagitis and resolving heartburn and both treatments were well tolerated. Expand